Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru
Descripción del Articulo
This study was made possible through the financial support of the Instituto Nacional de Salud (National Institute of Health, Lima, Peru) and the PROVAC Initiative of the Pan American Health Organization (Washington, DC, USA). This study was presented at 9th International Symposium of Pneumococci and...
| Autores: | , , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2015 |
| Institución: | Consejo Nacional de Ciencia Tecnología e Innovación |
| Repositorio: | CONCYTEC-Institucional |
| Lenguaje: | inglés |
| OAI Identifier: | oai:repositorio.concytec.gob.pe:20.500.12390/655 |
| Enlace del recurso: | https://hdl.handle.net/20.500.12390/655 https://doi.org/10.1016/j.vaccine.2014.12.039 |
| Nivel de acceso: | acceso abierto |
| Materia: | Pneumococcus vaccine 10-valent pneumococcal conjugate vaccine 13-valent pneumococcal vaccine acute otitis media |
| id |
CONC_02acdded6a01769a45c333ae5ee767ee |
|---|---|
| oai_identifier_str |
oai:repositorio.concytec.gob.pe:20.500.12390/655 |
| network_acronym_str |
CONC |
| network_name_str |
CONCYTEC-Institucional |
| repository_id_str |
4689 |
| dc.title.none.fl_str_mv |
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru |
| title |
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru |
| spellingShingle |
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru Mezones-Holguin E. Pneumococcus vaccine 10-valent pneumococcal conjugate vaccine 13-valent pneumococcal vaccine acute otitis media |
| title_short |
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru |
| title_full |
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru |
| title_fullStr |
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru |
| title_full_unstemmed |
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru |
| title_sort |
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru |
| author |
Mezones-Holguin E. |
| author_facet |
Mezones-Holguin E. Canelo-Aybar C. Clark A.D. Janusz C.B. Jaúregui B. Escobedo-Palza S. Hernandez A.V. Vega-Porras D. González M. Fiestas F. Toledo W. Michel F. Suárez V.J. |
| author_role |
author |
| author2 |
Canelo-Aybar C. Clark A.D. Janusz C.B. Jaúregui B. Escobedo-Palza S. Hernandez A.V. Vega-Porras D. González M. Fiestas F. Toledo W. Michel F. Suárez V.J. |
| author2_role |
author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Mezones-Holguin E. Canelo-Aybar C. Clark A.D. Janusz C.B. Jaúregui B. Escobedo-Palza S. Hernandez A.V. Vega-Porras D. González M. Fiestas F. Toledo W. Michel F. Suárez V.J. |
| dc.subject.none.fl_str_mv |
Pneumococcus vaccine |
| topic |
Pneumococcus vaccine 10-valent pneumococcal conjugate vaccine 13-valent pneumococcal vaccine acute otitis media |
| dc.subject.es_PE.fl_str_mv |
10-valent pneumococcal conjugate vaccine 13-valent pneumococcal vaccine acute otitis media |
| description |
This study was made possible through the financial support of the Instituto Nacional de Salud (National Institute of Health, Lima, Peru) and the PROVAC Initiative of the Pan American Health Organization (Washington, DC, USA). This study was presented at 9th International Symposium of Pneumococci and Pneumococcal Diseases, Hyderabad, India, March 2014, and supported by the National Council of Science, Technology and Technological Innovation of Peru (CONCYTEC) and International Clinical Epidemiology Network (INCLEN Trust). |
| publishDate |
2015 |
| dc.date.accessioned.none.fl_str_mv |
2024-05-30T23:13:38Z |
| dc.date.available.none.fl_str_mv |
2024-05-30T23:13:38Z |
| dc.date.issued.fl_str_mv |
2015 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12390/655 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.vaccine.2014.12.039 |
| dc.identifier.scopus.none.fl_str_mv |
2-s2.0-85047695497 |
| url |
https://hdl.handle.net/20.500.12390/655 https://doi.org/10.1016/j.vaccine.2014.12.039 |
| identifier_str_mv |
2-s2.0-85047695497 |
| dc.language.iso.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartof.none.fl_str_mv |
Vaccine |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Elsevier Ltd |
| publisher.none.fl_str_mv |
Elsevier Ltd |
| dc.source.none.fl_str_mv |
reponame:CONCYTEC-Institucional instname:Consejo Nacional de Ciencia Tecnología e Innovación instacron:CONCYTEC |
| instname_str |
Consejo Nacional de Ciencia Tecnología e Innovación |
| instacron_str |
CONCYTEC |
| institution |
CONCYTEC |
| reponame_str |
CONCYTEC-Institucional |
| collection |
CONCYTEC-Institucional |
| repository.name.fl_str_mv |
Repositorio Institucional CONCYTEC |
| repository.mail.fl_str_mv |
repositorio@concytec.gob.pe |
| _version_ |
1844883006440865792 |
| spelling |
Publicationrp01439600rp01441600rp01438600rp01443600rp01448600rp01447600rp01444600rp01445600rp01446600rp01442600rp01449600rp01440600rp01450600Mezones-Holguin E.Canelo-Aybar C.Clark A.D.Janusz C.B.Jaúregui B.Escobedo-Palza S.Hernandez A.V.Vega-Porras D.González M.Fiestas F.Toledo W.Michel F.Suárez V.J.2024-05-30T23:13:38Z2024-05-30T23:13:38Z2015https://hdl.handle.net/20.500.12390/655https://doi.org/10.1016/j.vaccine.2014.12.0392-s2.0-85047695497This study was made possible through the financial support of the Instituto Nacional de Salud (National Institute of Health, Lima, Peru) and the PROVAC Initiative of the Pan American Health Organization (Washington, DC, USA). This study was presented at 9th International Symposium of Pneumococci and Pneumococcal Diseases, Hyderabad, India, March 2014, and supported by the National Council of Science, Technology and Technological Innovation of Peru (CONCYTEC) and International Clinical Epidemiology Network (INCLEN Trust).Objective: To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children <5 years of age. Methods: The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization’s ProVac Initiative (version 2.0) was applied from the perspective of the Government of Peru. Twenty successive cohorts of children from birth to 5 years were evaluated. Clinical outcomes were pneumococcal pneumonia (PP), pneumococcal meningitis (PM), pneumococcal sepsis (PS) and acute otitis media from any causes (AOM). Measures included prevention of cases, neurological sequelae (NS), auditory sequelae (AS), deaths and disability adjusted life years (DALYs). A sensitivity analyses was also performed. Findings: For the 20 cohorts, net costs with PCV10 and PCV13 were US$ 363.26 million and US$ 408.26 million, respectively. PCV10 prevented 570,273 AOM; 79,937 PP; 2217 PM; 3049 PS; 282 NS; 173 AS; and 7512 deaths. PCV13 prevented 419,815 AOM; 112,331 PN; 3116 PM; 4285 PS; 404 NS; 248 AS; and 10,386 deaths. Avoided DALYs were 226,370 with PCV10 and 313,119 with PCV13. Saved treatment costs were US$ 37.39 million with PCV10 and US$ 47.22 million with PCV13. Costs per DALY averted were US$ 1605 for PCV10, and US$ 1304 for PCV13. Sensitivity analyses showed similar results. PCV13 has an extended dominance over PCV10. Conclusion: Both pneumococcal vaccines are cost effective in the Peruvian context. Although the net cost of vaccination with PCV10 is lower, PCV13 prevented more deaths, pneumococcal complications and sequelae. Costs per each prevented DALY were lower with PCV13. Thus, PCV13 would be the preferred policy; PCV10 would also be reasonable (and cost-saving relative to the status quo) if for some reason 13-valent were not feasible.Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica - ConcytecengElsevier LtdVaccineinfo:eu-repo/semantics/openAccessPneumococcus vaccine10-valent pneumococcal conjugate vaccine-113-valent pneumococcal vaccine-1acute otitis media-1Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peruinfo:eu-repo/semantics/articlereponame:CONCYTEC-Institucionalinstname:Consejo Nacional de Ciencia Tecnología e Innovacióninstacron:CONCYTEC20.500.12390/655oai:repositorio.concytec.gob.pe:20.500.12390/6552025-09-25 08:30:22.456http://purl.org/coar/access_right/c_14cbinfo:eu-repo/semantics/closedAccessmetadata only accesshttps://repositorio.concytec.gob.peRepositorio Institucional CONCYTECrepositorio@concytec.gob.pe#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="9d43d1f0-7835-496b-9bfc-f6ec89b83085"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru</Title> <PublishedIn> <Publication> <Title>Vaccine</Title> </Publication> </PublishedIn> <PublicationDate>2015</PublicationDate> <DOI>https://doi.org/10.1016/j.vaccine.2014.12.039</DOI> <SCP-Number>2-s2.0-85047695497</SCP-Number> <Authors> <Author> <DisplayName>Mezones-Holguin E.</DisplayName> <Person id="rp01439" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Canelo-Aybar C.</DisplayName> <Person id="rp01441" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Clark A.D.</DisplayName> <Person id="rp01438" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Janusz C.B.</DisplayName> <Person id="rp01443" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Jaúregui B.</DisplayName> <Person id="rp01448" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Escobedo-Palza S.</DisplayName> <Person id="rp01447" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Hernandez A.V.</DisplayName> <Person id="rp01444" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Vega-Porras D.</DisplayName> <Person id="rp01445" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>González M.</DisplayName> <Person id="rp01446" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Fiestas F.</DisplayName> <Person id="rp01442" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Toledo W.</DisplayName> <Person id="rp01449" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Michel F.</DisplayName> <Person id="rp01440" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Suárez V.J.</DisplayName> <Person id="rp01450" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Elsevier Ltd</DisplayName> <OrgUnit /> </Publisher> </Publishers> <Keyword>Pneumococcus vaccine</Keyword> <Keyword>10-valent pneumococcal conjugate vaccine</Keyword> <Keyword>13-valent pneumococcal vaccine</Keyword> <Keyword>acute otitis media</Keyword> <Abstract>Objective: To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children <5 years of age. Methods: The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization’s ProVac Initiative (version 2.0) was applied from the perspective of the Government of Peru. Twenty successive cohorts of children from birth to 5 years were evaluated. Clinical outcomes were pneumococcal pneumonia (PP), pneumococcal meningitis (PM), pneumococcal sepsis (PS) and acute otitis media from any causes (AOM). Measures included prevention of cases, neurological sequelae (NS), auditory sequelae (AS), deaths and disability adjusted life years (DALYs). A sensitivity analyses was also performed. Findings: For the 20 cohorts, net costs with PCV10 and PCV13 were US$ 363.26 million and US$ 408.26 million, respectively. PCV10 prevented 570,273 AOM; 79,937 PP; 2217 PM; 3049 PS; 282 NS; 173 AS; and 7512 deaths. PCV13 prevented 419,815 AOM; 112,331 PN; 3116 PM; 4285 PS; 404 NS; 248 AS; and 10,386 deaths. Avoided DALYs were 226,370 with PCV10 and 313,119 with PCV13. Saved treatment costs were US$ 37.39 million with PCV10 and US$ 47.22 million with PCV13. Costs per DALY averted were US$ 1605 for PCV10, and US$ 1304 for PCV13. Sensitivity analyses showed similar results. PCV13 has an extended dominance over PCV10. Conclusion: Both pneumococcal vaccines are cost effective in the Peruvian context. Although the net cost of vaccination with PCV10 is lower, PCV13 prevented more deaths, pneumococcal complications and sequelae. Costs per each prevented DALY were lower with PCV13. Thus, PCV13 would be the preferred policy; PCV10 would also be reasonable (and cost-saving relative to the status quo) if for some reason 13-valent were not feasible.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication> -1 |
| score |
13.871978 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
